Researchers at Helsinki University investigated how the genetic characteristics of ovarian cancer shape how tumor and immune cells communicate with each other and how BRCA1/2 mutations shape the cellular phenotypes and spatial interactions of the tumor microenvironment. “With the help of this revolutionary imaging technology and advanced data analysis, we…

Interpace Diagnostics Group has acquired the BioPharma services business of Cancer Genetics for approximately $23.5 million, while concurrently the buyer will receive a $27 million investment from private equity firm Ampersand Capital Partners. The deals are designed to expand Interpace into a leading provider of oncology testing and services across…

Cancer Genetics (CGI) said today it has terminated its planned merger with NovellusDx and will instead “pursue alternative strategic and financial transactions” intended to enhance shareholder value. “Based on difficulties we have had in advancing the merger process, as well as certain other factors, we believed it was in the…

Molecular biomarker and diagnostics company Cancer Genetics Inc. (CGI) announced it would merge with Israeli company NovellusDx, a leader in functional genomics, in a deal that will combine CGI’s test portfolio and tumor biology dataset with the next-generation sequencing and machine learning expertise of NovellusDx. When the merger is completed,…

In February, after a string of quarterly performances that missed Wall Street analysts’ expectations, a shrinking balance sheet, and stock price that had steadily declined to under $2 per share from a high of more than $23 four-and-a-half years earlier, Cancer Genetics (CGI) Inc.’s CEO of nearly eight years, Panna…

Precision medicine oncology company Cancer Genetics Inc., announced today that Panna Sharma, the company’s CEO since 2010 will be stepping down from his post. The company’s board of directors have named John A. (Jay) Roberts, currently serving as chief operating officer, as the interim CEO. “We would like to thank…

Cancer Genetics (CGI) said today it has received $1.1 million in net cash proceeds through the transfer of tax credits approved by the New Jersey Technology Business Tax Certificate Transfer (NOL) program of the New Jersey Economic Development Authority (NJEDA). “This non-dilutive capital will help to accelerate the development and…

Cancer Genetics, a precision medicine company focusing on oncology, reported record-high results for Q3 2017. The report released Thursday states that total revenues were $8.0 million—up 19% over Q3 2016 revenues of $6.8 million—with $4.2 million from biopharma services (up 10% since the same period last year), $2.9 million from…

Oncology precision medicine company Cancer Genetics (CGI) announced it will buy cancer drug discovery and preclinical services company vivoPharm in a cash and stock deal valued at $12 million. CGI said it expects the acquisition to strengthen its position as a provider of services for oncology discovery, in vivo and in vitro drug development, and…

Cancer Genetics has been chosen by eFFECTOR Therapeutics to provide clinical biomarker services for eFFECTOR’s cancer-fighting lead product candidate eFT508, the companies said today, through a collaboration whose value was not disclosed. The companies said they will co-develop strategies enabling eFFECTOR to further develop eFT508 as a single agent and…

Cancer Genetics (CGI) said today it plans to acquire Gentris, in an up-to-$6.25 million deal that the buyer said will significantly expand its client base beyond oncology diagnostics, through added capabilities in genomic profiling for clinical trials as well as in pharmacogenomics. “We view this acquisition as part of our…

Cancer Genetics said today it acquired Indian-based BioServe Biotechnologies for about $1.9 million, primarily in stock and other deferred payments, in a deal designed to help the buyer scale up its genetic analysis, bioinformatics, and manufacturing operations while capitalizing on clinical diagnostics and trial growth in India and the Asian…

African Americans and Latinos who smoke can develop specific epigenetic changes putting them particularly at risk for cancer says research that comes from one of the largest multiethnic studies yet of smoking’s influence on cancer risk. Researchers from the Keck School of Medicine analyzed the link between smoking and DNA…

Taking a man’s genetics into account can improve the predictive value of the most widely used biomarker in prostate cancer detection, researchers report. The findings, in the journal Nature Medicine, may help reduce the risk of prostate cancer overdiagnosis and improve the detection of aggressive disease. The study of more…

Epic Sciences, a diagnostics company applying a novel approach to classifying prostate and breast cancers to help guide therapy and detect disease recurrence announced it will partner with Fulgent Genetics for comprehensive genomic profiling of patients with metastatic breast cancer (MBC). The deal will leverage Fulgent’s CAP/CLIA next-generation sequencing capabilities…